CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme Corp. (NASDAQ: GENZ) announced that it has responded to a letter sent earlier today by Sanofi-Aventis relating to its unsolicited tender offer. Genzyme’s response reiterates the unanimous view of its board of directors that the $69-per-share offer price is not an appropriate starting point for discussions because it dramatically undervalues the company.
